Abstract

Creutzfeldt–Jakob Disease (CJD) is a fatal, currently incurable, neurodegenerative disease. The search for candidate treatments would be greatly facilitated by the availability of human cell-based models of prion disease. Recently, an induced pluripotent stem cell derived human cerebral organoid model was shown to take up and propagate human CJD prions. This model offers new opportunities to screen drug candidates for the treatment of human prion diseases in an entirely human genetic background. Here we provide the first evidence that human cerebral organoids can be a viable model for CJD drug screening by using an established anti-prion compound, pentosan polysulfate (PPS). PPS delayed prion propagation in a prophylactic-like treatment paradigm and also alleviated propagation when applied following establishment of infection in a therapeutic-like treatment paradigm. This study demonstrates the utility of cerebral organoids as the first human 3D cell culture system for screening therapeutic drug candidates for human prion diseases.

Details

Title
Human cerebral organoids as a therapeutic drug screening model for Creutzfeldt–Jakob disease
Author
Groveman, Bradley R. 1 ; Ferreira, Natalia C. 1 ; Foliaki, Simote T. 1 ; Walters, Ryan O. 1 ; Winkler, Clayton W. 1 ; Race, Brent 1 ; Hughson, Andrew G. 1 ; Zanusso, Gianluigi 2 ; Haigh, Cathryn L. 1 

 National Institute of Allergy and Infectious Diseases, National Institutes of Health, Laboratory of Persistent Viral Diseases, Division of Intramural Research, Rocky Mountain Laboratories, Hamilton, USA (GRID:grid.419681.3) (ISNI:0000 0001 2164 9667) 
 University of Verona, Department of Neurosciences, Biomedicine and Movement Sciences, Verona, Italy (GRID:grid.5611.3) (ISNI:0000 0004 1763 1124) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2704539151
Copyright
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.